RxDoctor Payments Data

Madaline McCray

Family · Moody, ALNPI 1700470911

Payments from drug & device makers

$2,449in general payments, 2019–2025

Across 139 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$471
  • GSK$440
  • Novo Nordisk$294
  • AstraZeneca$242
  • AbbVie$218
  • Corium, LLC$190
  • plus $594 from 13 others

What the payments were for

  • Food & beverage$2,449100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,449 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$13,033
Medicare patients
76
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$77,635
JanuviaSitagliptin Phosphate64$56,332
JardianceEmpagliflozin51$46,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$41,405
MounjaroTirzepatide35$38,373
TrulicityDulaglutide18$27,155
EliquisApixaban26$25,018
FarxigaDapagliflozin Propanediol22$19,573
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$12,964
MyrbetriqMirabegron15$8,491
Praluent PenAlirocumab11$7,470
Tresiba Flextouch U-100Insulin Degludec13$7,038
Rosuvastatin Calcium256$6,512
Wixela InhubFluticasone Propion/Salmeterol12$3,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$294$77,63571 claims
Lilly USA, LLCMounjaro, Trulicity$471$65,52753 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$440$57,10376 claims
Boehringer IngelheimJardiance$101$46,76051 claims
PfizerEliquis$105$25,01826 claims
AstraZenecaFarxiga$242$19,57322 claims
AbbVieSynthroid$218$1,13215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.

Other family in Moody

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →